Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade

✍ Scribed by Takeshi Kihara; Shun Shimohama; Hideyuki Sawada; Kazuhiro Honda; Tomoki Nakamizo; Rie Kanki; Hiroshi Yamashita; Akinori Akaike

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: English
• Weight: 576 KB
• Volume: 70
• Category: Article
• ISSN: 0360-4012
• DOI: 10.1002/jnr.10426

✦ Synopsis

Abstract

Glutamate, one of the excitatory neurotransmitters, contributes to the neuronal death associated with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and with ischemia. In Alzheimer's disease brains, there is a decreased number of dopamine D2 receptors, which might cause neuronal dysfunction or death. In the present study, bromocriptine exerted a protective effect against glutamate‐induced cytotoxicity in rat cortical neurons. This neuroprotective effect was mediated via D2 receptors, because it was attenuated by domperidone, a D2 dopaminergic receptor antagonist. Another dopamine D2 agonist, quinpirole, also protected cells against glutamate toxicity. D2 agonists protected cells from calcium influx, nitric oxide, and peroxynitrite toxicity, which are thought to be the mediators of glutamate toxicity. The phosphatidylinositol 3 kinase (PI3K) inhibitor (LY294002) inhibited this neuroprotective effect of bromocriptine, in contrast to the mitogen‐activated protein kinase kinase (MAPKK) inhibitor (PD98059), which did not counter the protective effect. Furthermore, Akt protein kinase, which is an effector of PI3K, was activated by bromocriptine, and the antiapoptotic protein Bcl‐2 was up‐regulated by bromocriptine treatment. These results suggest that D2 dopaminergic receptor activation plays an important role in neuroprotection against glutamate cytotoxicity and that the up‐regulation of Bcl‐2 expression via the PI3K cascade is, at least partially, involved in this effect. © 2002 Wiley‐Liss, Inc.